Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 34 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. US 9624498

    Methods and compositions for regulation of zinc finger protein expression

    Sangamo Biosciences, Inc. · Granted Apr 18, 2017 · Expires Apr 13, 2037

    granted

  2. US 9623040

    Immunomodulation by controlling expression levels of microRNAs in dendritic cells

    The Regents of the University of California · Granted Apr 18, 2017 · Expires Apr 13, 2037

    granted

  3. US 9617539

    Modulation of UBE3A-ATS expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 11, 2017 · Expires Apr 6, 2037

    granted

  4. US 9616048

    Anti-depression compounds

    The Board of Regents of the University of Texas System · Granted Apr 11, 2017 · Expires Apr 6, 2037

    granted

  5. US 9617540

    Compounds and methods for modulating gene expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 11, 2017 · Expires Apr 6, 2037

    granted

  6. US 9611230

    1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease

    PTC THERAPEUTICS, INC. · Granted Apr 4, 2017 · Expires Mar 30, 2037

    granted

  7. US 9611322

    Fusions of antibodies to CD38 and attenuated interferon alpha

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Apr 4, 2017 · Expires Mar 30, 2037

    granted

  8. US 9605259

    Compounds and methods for modulating protein expression

    Ionis Pharmaceuticals, Inc. · Granted Mar 28, 2017 · Expires Mar 23, 2037

    granted

  9. US 9605077

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    PRECISION BIOLOGICS, INC. · Granted Mar 28, 2017 · Expires Mar 23, 2037

    granted

  10. US 9605263

    Compositions for modulating C9ORF72 expression

    Ionis Pharmaceuticals, Inc. · Granted Mar 28, 2017 · Expires Mar 23, 2037

    granted

  11. US 9592207

    Intranasal administration of ketamine to treat depression

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 14, 2017 · Expires Mar 9, 2037

    granted

  12. US 9592255

    Scaffold-free three dimensional nerve fibroblast constructs

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Mar 14, 2017 · Expires Mar 9, 2037

    granted

  13. US 9592309

    Positron emission tomography probe to monitor selected sugar metabolism in vivo

    The Regents of the University of California · Granted Mar 14, 2017 · Expires Mar 9, 2037

    granted

  14. US 9592290

    Monoclonal antibody therapy for pancreas cancer

    PRECISION BIOLOGICS, INC. · Granted Mar 14, 2017 · Expires Mar 9, 2037

    granted

  15. US 9593151

    Use of fusion protein

    East China University of Science and Technology · Granted Mar 14, 2017 · Expires Mar 9, 2037

    granted

  16. US 9593333

    Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations

    Ionis Pharmaceuticals, Inc. · Granted Mar 14, 2017 · Expires Mar 9, 2037

    granted

  17. US 9587240

    Compositions and methods for inhibiting expression of a target gene

    Alnylam Pharmaceuticals, Inc. · Granted Mar 7, 2017 · Expires Mar 2, 2037

    granted

  18. US 9574193

    Methods and compositions for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 21, 2017 · Expires Feb 16, 2037

    granted

  19. US 9574191

    Selective inhibition of polyglutamine protein expression

    The Board of Regents of the University of Texas System · Granted Feb 21, 2017 · Expires Feb 16, 2037

    granted

  20. US 9566295

    GNAQ targeted dsRNA compositions and methods for inhibiting expression

    Alnylam Pharmaceuticals, Inc. · Granted Feb 14, 2017 · Expires Feb 9, 2037

    granted

  21. US 9567592

    Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell

    The Regents of the University of California · Granted Feb 14, 2017 · Expires Feb 9, 2037

    granted

  22. US 9567587

    Antisense modulation of GCCR expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 14, 2017 · Expires Feb 9, 2037

    granted

  23. US 9567588

    Modulation of androgen receptor expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 14, 2017 · Expires Feb 9, 2037

    granted

  24. US 9561229

    Emulsion formulations of aprepitant

    Heron Therapeutics, Inc. · Granted Feb 7, 2017 · Expires Feb 2, 2037

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.